AHNTI US Agenda

The US represents the world's largest and most dynamic animal health market, and we're seeing unprecedented investment and expansion from global leaders – from Dechra establishing its new global headquarters in Boston to Latin American companies expanding their North American footprint.

This panel will explore the strategic rationale behind these major moves: what makes the US market uniquely attractive, how global leaders navigate regulatory complexity and competitive dynamics, and what this wave of international investment signals about where the industry is heading.

Understanding outcomes and sharing that data up and down the value chain could be the single biggest accelerator of growth across the whole market in the years ahead. In this session Dottie will discuss how MVH are tackling the associated challenges and thinking about what this future could hold.

• The How: Developing an owner assessment of pet health and incorporating that into the medical record in a systematic and quantifiable way and combining this with the vet assessment
• The How: AI enabling the creation of valid and reliable tools
• Outcome: How can this data be used to de-risk investment in new biopharma, diagnostic, nutrition and tech solutions
• Outcome: Incorporating health outcomes data into your daily practice, from single clinics to large groups, the clinical patient management use case 

Placing the pet owner and their companions at the center of the entire animal health value chain, how do we design a future where everyone in this ecosystem wins? We’ll discuss…

• The full spectrum of information that helps define prevalence of disease and wellness needs
• Pet owners need for convenience, transparency and accessibility
• How data unlocks accessibility, affordability, personalization and prediction
• In order for this vision to happen, what are the roadblocks we need to overcome?

Instead of asking whether animal health can learn from human pharma’s playbook, this session asks what structural advantages animal health has that could make AI deployment faster, cheaper, and more impactful.

Lower regulatory burden. Faster trial timelines. Lower cost of failure. Access to rich real-world data from PIMS and practice networks. A more concentrated market with fewer stakeholders. These are genuine structural advantages, and they’re being exploited by companies across the value chain, from target identification to manufacturing optimisation.

As antimicrobial use declines, genetic complexity rises, and labour and climate pressures mount, nutrition is shifting from a performance input to an integrated management tool across health, immunity, and resilience. The science is advancing. The barrier is proof.

ROI is difficult to demonstrate consistently across variable genetics, geographies, and production systems. The validation models needed to generate commercially credible, farm-level evidence have not been built. This session will explore where functional nutrition is creating the greatest combined value, why the commercial case remains so hard to make in real production settings, and what it takes to construct the validation frameworks that unlock adoption at scale.

Unlocking economic and medical advancement for the pet owners we serve

• Data we should start capturing and what it would mean
• Patient safety and identifying training opportunities
• Connect with pet owners
• Connect with vendors
• Measure the success of launching products
• Deciding which products should be used based on client population.

This session will examine where the inefficiencies are, what’s actually changing, and what a best-in-class development programme looks like today. Critically, it will also address the adoption gap: if you design a trial without thinking about how the product will be used in practice, you’re building in a commercialisation problem from day one.

A decade of sustainability commitment has not built a functioning financial model. Costs remain concentrated at the farm level, consumer premium has not materialized, and verification frameworks are too expensive and inconsistent to distribute value fairly across the chain.

The context is shifting. Financial regulation, mandatory climate reporting, and financed emissions entering the banking sector are making sustainability a capital access issue rather than a marketing one. The architecture to respond does not yet exist.

This session will explore what a commercially viable sustainability model actually requires: producer-first value propositions that stack productivity, regenerative outcomes, and financial incentives beyond carbon; verification frameworks that reduce cost burden and reward outcomes fairly; and how inset, offset, and new market entrants need to be structured to protect rather than squeeze the producer.